|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000255690 |
Summary for TRIL |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000255690 | Gene symbol | TRIL |
| Gene name | TLR4 interactor with leucine rich repeats | |
| HGNC | 22200 | |
| Entrez ID | 9865 | |
| Gene type | protein_coding | |
| Synonyms | TRIL|KIAA0644 | |
| UniProtAcc | Q7L0X0 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for TRIL |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| TRIL | 8.17e+02 | -1.39e+00 | 4.12e-01 | -3.37e+00 | 7.51e-04 | 4.11e-03 | KIRP |
Top |
Sex-biased somatic mutation for TRIL |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for TRIL |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg00551143 | chr7:28959244 | CGI:chr7:28955615-28958925 | promoter | 4.17e-01 | 2.94e-01 | 2.39e+00 | 1.69e-02 | 3.28e-02 | 1.22e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg24426072 | chr7:28957557 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 1.30e-01 | 2.31e-02 | 5.36e+00 | 8.45e-08 | 4.32e-07 | 1.07e-01 |
| KIRC | cg19929126 | chr7:28958579 | CGI:chr7:28955615-28958925 | promoter | 1.66e-01 | 2.09e-02 | 3.73e+00 | 1.94e-04 | 3.66e-04 | 1.45e-01 |
| KIRC | cg07702750 | chr7:28958598 | CGI:chr7:28955615-28958925 | promoter | 1.74e-01 | 2.74e-02 | 3.74e+00 | 1.80e-04 | 3.43e-04 | 1.47e-01 |
| KIRC | cg24853724 | chr7:28957787 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 2.21e-01 | 8.30e-02 | 5.19e+00 | 2.09e-07 | 9.38e-07 | 1.38e-01 |
| HNSC | cg15444947 | chr7:28956875 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 1.42e-01 | 3.82e-02 | 3.45e+00 | 5.56e-04 | 1.10e-03 | 1.04e-01 |
| HNSC | cg10479082 | chr7:28957023 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 1.98e-01 | 3.42e-02 | 3.89e+00 | 9.92e-05 | 2.57e-04 | 1.64e-01 |
| HNSC | cg14996783 | chr7:28957286 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 1.26e-01 | 1.89e-02 | 3.90e+00 | 9.73e-05 | 2.53e-04 | 1.07e-01 |
| HNSC | cg24426072 | chr7:28957557 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 1.63e-01 | 3.13e-02 | 4.66e+00 | 3.22e-06 | 1.50e-05 | 1.32e-01 |
| HNSC | cg07255674 | chr7:28956633 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 1.62e-01 | 5.55e-02 | 4.08e+00 | 4.59e-05 | 1.35e-04 | 1.06e-01 |
| LUSC | cg22675801 | chr7:28958730 | CGI:chr7:28955615-28958925 | promoter | 2.82e-01 | 1.42e-01 | 2.65e+00 | 8.01e-03 | 1.17e-02 | 1.40e-01 |
| LUSC | cg10479082 | chr7:28957023 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 2.26e-01 | 6.08e-02 | 2.13e+00 | 3.33e-02 | 3.59e-02 | 1.65e-01 |
| LUSC | cg14996783 | chr7:28957286 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 1.83e-01 | 2.15e-02 | 2.21e+00 | 2.72e-02 | 3.05e-02 | 1.62e-01 |
| LUSC | cg24426072 | chr7:28957557 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 2.23e-01 | 3.75e-02 | 3.09e+00 | 2.03e-03 | 4.23e-03 | 1.86e-01 |
| LUSC | cg04823311 | chr7:28957869 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 1.33e-01 | 1.84e-02 | 2.72e+00 | 6.48e-03 | 9.92e-03 | 1.15e-01 |
| LUSC | cg19929126 | chr7:28958579 | CGI:chr7:28955615-28958925 | promoter | 1.39e-01 | 1.41e-02 | 3.52e+00 | 4.34e-04 | 1.52e-03 | 1.25e-01 |
| LUSC | cg07702750 | chr7:28958598 | CGI:chr7:28955615-28958925 | promoter | 1.35e-01 | 1.49e-02 | 3.30e+00 | 9.77e-04 | 2.56e-03 | 1.20e-01 |
| LUSC | cg19198568 | chr7:28958250 | CGI:chr7:28955615-28958925 | UTR,promoter,exon,gene body | 2.67e-01 | 1.51e-01 | 2.68e+00 | 7.36e-03 | 1.09e-02 | 1.15e-01 |
| LUSC | cg22348673 | chr7:28958309 | CGI:chr7:28955615-28958925 | promoter | 2.02e-01 | 8.65e-02 | 2.94e+00 | 3.24e-03 | 5.92e-03 | 1.15e-01 |
| LUSC | cg00551143 | chr7:28959244 | CGI:chr7:28955615-28958925 | promoter | 5.56e-01 | 7.32e-01 | -2.56e+00 | 1.04e-02 | 1.43e-02 | -1.76e-01 |
| COAD | cg14709460 | chr7:28958462 | CGI:chr7:28955615-28958925 | promoter | 1.60e-01 | 2.66e-02 | 2.03e+00 | 4.21e-02 | 4.38e-02 | 1.33e-01 |
| COAD | cg22675801 | chr7:28958730 | CGI:chr7:28955615-28958925 | promoter | 3.99e-01 | 2.39e-01 | 2.64e+00 | 8.37e-03 | 1.25e-02 | 1.60e-01 |
| COAD | cg19929126 | chr7:28958579 | CGI:chr7:28955615-28958925 | promoter | 2.87e-01 | 4.03e-02 | 2.40e+00 | 1.66e-02 | 2.14e-02 | 2.46e-01 |
| COAD | cg07702750 | chr7:28958598 | CGI:chr7:28955615-28958925 | promoter | 2.76e-01 | 4.91e-02 | 2.26e+00 | 2.41e-02 | 2.85e-02 | 2.27e-01 |
| BLCA | cg19499748 | chr7:28958165 | CGI:chr7:28955615-28958925 | UTR,promoter,exon,gene body | 3.90e-01 | 2.34e-01 | 2.55e+00 | 1.09e-02 | 1.51e-02 | 1.56e-01 |
| BLCA | cg22675801 | chr7:28958730 | CGI:chr7:28955615-28958925 | promoter | 3.78e-01 | 2.39e-01 | 1.99e+00 | 4.61e-02 | 4.69e-02 | 1.39e-01 |
| BLCA | cg04823311 | chr7:28957869 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 2.85e-01 | 2.63e-02 | 2.77e+00 | 5.55e-03 | 8.84e-03 | 2.59e-01 |
| BLCA | cg24853724 | chr7:28957787 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 3.50e-01 | 1.73e-01 | 2.30e+00 | 2.12e-02 | 2.56e-02 | 1.77e-01 |
| BLCA | cg19198568 | chr7:28958250 | CGI:chr7:28955615-28958925 | UTR,promoter,exon,gene body | 3.91e-01 | 1.94e-01 | 2.53e+00 | 1.14e-02 | 1.56e-02 | 1.97e-01 |
| BLCA | cg22348673 | chr7:28958309 | CGI:chr7:28955615-28958925 | promoter | 3.41e-01 | 1.39e-01 | 2.20e+00 | 2.76e-02 | 3.15e-02 | 2.02e-01 |
| BLCA | cg21572621 | chr7:28958453 | CGI:chr7:28955615-28958925 | promoter | 2.36e-01 | 9.05e-02 | 2.23e+00 | 2.55e-02 | 2.96e-02 | 1.45e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg00551143 | chr7:28959244 | CGI:chr7:28955615-28958925 | promoter | 4.17e-01 | 5.60e-01 | -7.50e+00 | 6.29e-14 | 2.11e-13 | -1.43e-01 |
| LUAD | cg00551143 | chr7:28959244 | CGI:chr7:28955615-28958925 | promoter | 5.83e-01 | 7.41e-01 | -2.64e+00 | 8.37e-03 | 1.39e-02 | -1.58e-01 |
| HNSC | cg22675801 | chr7:28958730 | CGI:chr7:28955615-28958925 | promoter | 2.60e-01 | 1.52e-01 | 2.09e+00 | 3.64e-02 | 4.02e-02 | 1.08e-01 |
| HNSC | cg13560901 | chr7:28958924 | CGI:chr7:28955615-28958925 | promoter | 3.80e-01 | 2.56e-01 | 2.70e+00 | 6.87e-03 | 1.54e-02 | 1.23e-01 |
| HNSC | cg00551143 | chr7:28959244 | CGI:chr7:28955615-28958925 | promoter | 5.25e-01 | 3.54e-01 | 2.38e+00 | 1.75e-02 | 2.55e-02 | 1.71e-01 |
| COAD | cg19499748 | chr7:28958165 | CGI:chr7:28955615-28958925 | UTR,promoter,exon,gene body | 3.64e-01 | 2.29e-01 | 2.77e+00 | 5.68e-03 | 1.04e-02 | 1.36e-01 |
| COAD | cg14996783 | chr7:28957286 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 2.50e-01 | 2.31e-02 | 2.39e+00 | 1.67e-02 | 2.28e-02 | 2.27e-01 |
| COAD | cg24426072 | chr7:28957557 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 2.88e-01 | 5.65e-02 | 2.14e+00 | 3.21e-02 | 3.64e-02 | 2.32e-01 |
| COAD | cg22348673 | chr7:28958309 | CGI:chr7:28955615-28958925 | promoter | 2.75e-01 | 1.02e-01 | 2.22e+00 | 2.67e-02 | 3.19e-02 | 1.73e-01 |
| COAD | cg00551143 | chr7:28959244 | CGI:chr7:28955615-28958925 | promoter | 7.68e-01 | 8.83e-01 | -2.02e+00 | 4.32e-02 | 4.49e-02 | -1.15e-01 |
| KIRP | cg15444947 | chr7:28956875 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 1.41e-01 | 2.91e-02 | 2.36e+00 | 1.83e-02 | 2.52e-02 | 1.12e-01 |
| KIRP | cg10479082 | chr7:28957023 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 1.49e-01 | 1.74e-02 | 2.15e+00 | 3.13e-02 | 3.63e-02 | 1.32e-01 |
| KIRP | cg24426072 | chr7:28957557 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 1.71e-01 | 2.66e-02 | 3.21e+00 | 1.31e-03 | 4.57e-03 | 1.45e-01 |
| KIRP | cg04823311 | chr7:28957869 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 1.59e-01 | 1.85e-02 | 2.41e+00 | 1.61e-02 | 2.31e-02 | 1.41e-01 |
| KIRP | cg24853724 | chr7:28957787 | CGI:chr7:28955615-28958925 | promoter,exon,CDS,gene body | 2.62e-01 | 9.57e-02 | 2.96e+00 | 3.07e-03 | 7.80e-03 | 1.67e-01 |
| KIRP | cg19198568 | chr7:28958250 | CGI:chr7:28955615-28958925 | UTR,promoter,exon,gene body | 2.37e-01 | 1.13e-01 | 2.03e+00 | 4.27e-02 | 4.48e-02 | 1.24e-01 |
| KIRP | cg21572621 | chr7:28958453 | CGI:chr7:28955615-28958925 | promoter | 1.65e-01 | 4.85e-02 | 1.96e+00 | 4.97e-02 | 4.97e-02 | 1.17e-01 |
Top |
Exon skipping events with PSI in TCGA for TRIL |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for TRIL |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for TRIL |
| TFs related to TRIL. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| ACC | DNMT1 | TRIL | 4.08e+00 | 9.83e-01 | 3.20e+00 | 6.73e-03 | Male-biased |
| ACC | ZNF543 | TRIL | 4.21e+00 | 9.83e-01 | 3.39e+00 | 8.73e-03 | Male-biased |
| ACC | ZNF682 | TRIL | 4.21e+00 | 9.86e-01 | 3.28e+00 | 5.68e-03 | Male-biased |
| BRCA | KLF3 | TRIL | 2.95e+00 | 2.19e-03 | 4.64e+00 | 9.90e-01 | Female-biased |
| BRCA | PRDM6 | TRIL | 4.39e+00 | 9.91e-01 | 1.87e+00 | 1.74e-04 | Male-biased |
| BRCA | SOX7 | TRIL | 4.95e+00 | 9.86e-01 | 3.72e+00 | 1.02e-02 | Male-biased |
| BRCA | STAT2 | TRIL | 4.51e+00 | 9.91e-01 | 2.72e+00 | 1.89e-03 | Male-biased |
| BRCA | ZIC2 | TRIL | 2.50e+00 | 2.09e-03 | 4.20e+00 | 9.81e-01 | Female-biased |
| BRCA | ZNF101 | TRIL | 2.95e+00 | 3.80e-03 | 4.47e+00 | 9.86e-01 | Female-biased |
| BRCA | ZNF182 | TRIL | 4.52e+00 | 9.93e-01 | 2.08e+00 | 2.34e-04 | Male-biased |
| BRCA | ZNF235 | TRIL | 4.31e+00 | 9.90e-01 | 1.60e+00 | 9.08e-05 | Male-biased |
| BRCA | ZNF287 | TRIL | 4.37e+00 | 9.91e-01 | 1.79e+00 | 1.42e-04 | Male-biased |
| BRCA | ZNF331 | TRIL | 2.65e+00 | 1.44e-03 | 4.48e+00 | 9.88e-01 | Female-biased |
| BRCA | ZNF431 | TRIL | 3.19e+00 | 6.33e-03 | 4.54e+00 | 9.84e-01 | Female-biased |
| BRCA | ZNF487 | TRIL | 4.44e+00 | 9.92e-01 | 1.96e+00 | 2.02e-04 | Male-biased |
| BRCA | ZNF530 | TRIL | 2.93e+00 | 4.04e-03 | 4.42e+00 | 9.85e-01 | Female-biased |
| BRCA | ZNF534 | TRIL | 3.39e+00 | 1.05e-02 | 4.59e+00 | 9.81e-01 | Female-biased |
| BRCA | ZNF616 | TRIL | 3.36e+00 | 7.26e-03 | 4.68e+00 | 9.86e-01 | Female-biased |
| BRCA | ZNF682 | TRIL | 3.10e+00 | 6.41e-03 | 4.45e+00 | 9.83e-01 | Female-biased |
| BRCA | ZNF701 | TRIL | 3.33e+00 | 1.00e-02 | 4.54e+00 | 9.81e-01 | Female-biased |
| BRCA | ZNF860 | TRIL | 3.01e+00 | 3.69e-03 | 4.54e+00 | 9.87e-01 | Female-biased |
| DLBC | PRDM6 | TRIL | 3.21e+00 | 4.56e-04 | 5.02e+00 | 9.97e-01 | Female-biased |
| DLBC | STAT2 | TRIL | 2.90e+00 | 3.01e-03 | 4.11e+00 | 9.85e-01 | Female-biased |
| DLBC | ZNF182 | TRIL | 3.41e+00 | 1.45e-03 | 4.85e+00 | 9.95e-01 | Female-biased |
| DLBC | ZNF235 | TRIL | 3.35e+00 | 2.46e-04 | 5.38e+00 | 9.98e-01 | Female-biased |
| DLBC | ZNF287 | TRIL | 3.44e+00 | 4.06e-04 | 5.30e+00 | 9.98e-01 | Female-biased |
| DLBC | ZNF487 | TRIL | 3.37e+00 | 5.20e-04 | 5.14e+00 | 9.97e-01 | Female-biased |
| ESCA | KLF7 | TRIL | 4.24e+00 | 9.81e-01 | 3.54e+00 | 1.10e-02 | Male-biased |
| ESCA | KLF9 | TRIL | 4.20e+00 | 9.80e-01 | 3.49e+00 | 1.06e-02 | Male-biased |
| GBM | ZNF101 | TRIL | 3.61e+00 | 1.43e-02 | 4.54e+00 | 9.80e-01 | Female-biased |
| MESO | SOX21 | TRIL | 3.99e+00 | 1.21e-02 | 5.21e+00 | 9.85e-01 | Female-biased |
| MESO | SOX4 | TRIL | 3.70e+00 | 9.22e-03 | 5.01e+00 | 9.87e-01 | Female-biased |
| MESO | SOX7 | TRIL | 3.65e+00 | 6.12e-03 | 5.09e+00 | 9.91e-01 | Female-biased |
| MESO | STAT2 | TRIL | 2.59e+00 | 6.04e-04 | 4.64e+00 | 9.94e-01 | Female-biased |
| MESO | ZNF182 | TRIL | 2.43e+00 | 3.93e-03 | 3.97e+00 | 9.81e-01 | Female-biased |
| PCPG | BATF | TRIL | 3.94e+00 | 1.26e-02 | 4.69e+00 | 9.83e-01 | Female-biased |
| PCPG | SOX21 | TRIL | 3.79e+00 | 7.13e-03 | 4.67e+00 | 9.88e-01 | Female-biased |
| PCPG | SOX4 | TRIL | 3.52e+00 | 4.36e-03 | 4.51e+00 | 9.90e-01 | Female-biased |
| PCPG | SOX7 | TRIL | 3.41e+00 | 2.85e-03 | 4.49e+00 | 9.91e-01 | Female-biased |
| PCPG | STAT2 | TRIL | 2.93e+00 | 2.38e-03 | 4.04e+00 | 9.85e-01 | Female-biased |
| PCPG | TWIST1 | TRIL | 3.42e+00 | 4.74e-03 | 4.39e+00 | 9.88e-01 | Female-biased |
| TRIL related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for TRIL |
| RBPs related to ES in TRIL. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| TRIL related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs17154049 | chr7:26600653:G:A | - | 0.127973435873615 | 0.0415045170408951 | SARC | Female-baised eQTL |
| rs11979831 | chr7:29805543:A:G | - | 0.101789011654639 | 0.0251019924147292 | LUSC | Female-baised eQTL |
| rs7782203 | chr7:32415280:G:A | - | 0.125841031778132 | 0.0268866218016519 | LUSC | Female-baised eQTL |
| rs10281835 | chr7:32414546:T:C | - | 0.124892426255301 | 0.0294897830249758 | LUSC | Female-baised eQTL |
| rs79925923 | chr7:30845908:T:G | - | 0.0793158666392349 | 0.0480856829227797 | LGG | Female-baised eQTL |
| rs4338001 | chr7:33661468:T:A | - | 0.0695308408304002 | 7.87716545722447e-05 | LUAD | Female-baised eQTL |
| rs73692615 | chr7:33652376:C:T | - | 0.0691564401756052 | 8.95391218954131e-05 | LUAD | Female-baised eQTL |
| rs12374818 | chr7:33654496:G:A | - | 0.0691564401756052 | 8.95391218954131e-05 | LUAD | Female-baised eQTL |
| rs12374953 | chr7:33654520:T:A | - | 0.0691564401756052 | 8.95391218954131e-05 | LUAD | Female-baised eQTL |
| rs73692612 | chr7:33650812:G:T | - | 0.0667501377950528 | 0.0001543024707868 | LUAD | Female-baised eQTL |
| rs73692611 | chr7:33649476:G:A | - | 0.0666048450326481 | 0.000161633079080528 | LUAD | Female-baised eQTL |
| rs56113871 | chr7:33649873:G:T | - | 0.0666048450326481 | 0.000161633079080528 | LUAD | Female-baised eQTL |
| rs57074081 | chr7:33650313:C:T | - | 0.0666048450326481 | 0.000161633079080528 | LUAD | Female-baised eQTL |
| rs6971342 | chr7:33656949:G:A | - | 0.0584126152945863 | 0.00100053606227488 | LUAD | Female-baised eQTL |
| rs13242065 | chr7:23448097:G:A | - | 0.0523319296030726 | 0.00535855175281631 | LUAD | Female-baised eQTL |
| rs35555978 | chr7:29187522:G:C | - | 0.045183631014523 | 0.00556096559174796 | LUAD | Female-baised eQTL |
| rs11979222 | chr7:33379151:C:G | - | 0.0532314172996486 | 0.00575086226553845 | LUAD | Female-baised eQTL |
| rs73097809 | chr7:33666219:T:C | - | 0.0491330909311623 | 0.00592288400362375 | LUAD | Female-baised eQTL |
| rs12700940 | chr7:29187948:C:G | - | 0.0425787666509317 | 0.00781028980033476 | LUAD | Female-baised eQTL |
| rs2245678 | chr7:25228757:G:A | - | -0.0478037703639442 | 0.00831057275478244 | LUAD | Female-baised eQTL |
| rs17157612 | chr7:29186219:A:G | - | 0.0400887467119867 | 0.0145159705406736 | LUAD | Female-baised eQTL |
| rs11771123 | chr7:32013949:C:A | - | 0.0420906734074497 | 0.0161176665427874 | LUAD | Female-baised eQTL |
| rs12673065 | chr7:33883952:A:G | - | 0.0337442663407342 | 0.0169291488683269 | LUAD | Female-baised eQTL |
| rs75816476 | chr7:29177536:G:C | - | 0.0377747654371449 | 0.0198293311809099 | LUAD | Female-baised eQTL |
| rs734580 | chr7:35500681:A:G | - | 0.0387141676873961 | 0.0205387633289375 | LUAD | Female-baised eQTL |
| rs73091610 | chr7:35506971:C:A | - | 0.0387141676873961 | 0.0205387633289375 | LUAD | Female-baised eQTL |
| rs59550164 | chr7:29178718:G:A | - | 0.0371456733894461 | 0.0223409842728663 | LUAD | Female-baised eQTL |
| rs35464056 | chr7:29180776:G:T | - | 0.0370996278621024 | 0.022747026324996 | LUAD | Female-baised eQTL |
| rs34830418 | chr7:29180908:C:T | - | 0.0370996278621024 | 0.022747026324996 | LUAD | Female-baised eQTL |
| rs60905785 | chr7:29162926:C:T | - | 0.0370596653058181 | 0.0230260424489202 | LUAD | Female-baised eQTL |
| rs35357398 | chr7:29183142:C:T | - | 0.0370334252459322 | 0.0231306797006495 | LUAD | Female-baised eQTL |
| rs34337883 | chr7:29185306:C:A | - | 0.0365011400373031 | 0.0255426467631154 | LUAD | Female-baised eQTL |
| rs28647177 | chr7:35515856:C:T | - | 0.0339479470713089 | 0.0287474875818909 | LUAD | Female-baised eQTL |
| rs13237997 | chr7:29167941:G:A | - | 0.0350340579649538 | 0.0294668170786225 | LUAD | Female-baised eQTL |
| rs73306215 | chr7:29174353:T:C | - | 0.0355302271672168 | 0.0299236831768182 | LUAD | Female-baised eQTL |
| rs13238687 | chr7:29165215:C:G | - | 0.0345582327220768 | 0.0322006478436202 | LUAD | Female-baised eQTL |
| rs34470328 | chr7:29161740:C:T | - | 0.0349276546110742 | 0.0336083105617712 | LUAD | Female-baised eQTL |
| rs35481765 | chr7:29162400:A:G | - | 0.0349276546110742 | 0.0336083105617712 | LUAD | Female-baised eQTL |
| rs56997419 | chr7:29162712:C:T | - | 0.0349276546110742 | 0.0336083105617712 | LUAD | Female-baised eQTL |
| rs35681573 | chr7:29180798:A:G | - | 0.0341685944702853 | 0.0370939110976771 | LUAD | Female-baised eQTL |
| rs11973415 | chr7:29163376:A:C | - | 0.0339749600922614 | 0.0375646071650848 | LUAD | Female-baised eQTL |
| rs10234832 | chr7:30564175:T:C | - | 0.0343236032146105 | 0.0415762652862259 | LUAD | Female-baised eQTL |
| rs11979687 | chr7:29169104:T:C | - | 0.0324974334384682 | 0.0429842732095417 | LUAD | Female-baised eQTL |
| rs28421111 | chr7:29167900:C:T | - | 0.031999160512811 | 0.0472292419543691 | LUAD | Female-baised eQTL |
| rs13225290 | chr7:29168213:T:C | - | 0.031999160512811 | 0.0472292419543691 | LUAD | Female-baised eQTL |
| rs77505573 | chr7:30795216:A:G | - | 0.0882902611236677 | 0.00962656480108438 | COAD | Female-baised eQTL |
| rs6962456 | chr7:30769912:C:T | - | 0.0917180766787104 | 0.0144663469506965 | COAD | Female-baised eQTL |
| rs78059384 | chr7:30772909:C:T | - | 0.0917180766787104 | 0.0144663469506965 | COAD | Female-baised eQTL |
| rs76359161 | chr7:30775620:A:G | - | 0.0917180766787104 | 0.0144663469506965 | COAD | Female-baised eQTL |
| rs77967702 | chr7:30774075:C:G | - | 0.091683866225526 | 0.0145844817082633 | COAD | Female-baised eQTL |
| rs57177267 | chr7:30801386:G:T | - | 0.0799790876072649 | 0.0231198817546383 | COAD | Female-baised eQTL |
| rs6948318 | chr7:19714894:C:A | - | 0.0832334010959278 | 0.0273930480392518 | COAD | Female-baised eQTL |
| rs17141832 | chr7:19717087:C:A | - | 0.0832334010959278 | 0.0273930480392518 | COAD | Female-baised eQTL |
| rs17141819 | chr7:19713698:G:A | - | 0.0831150197595428 | 0.027777929396668 | COAD | Female-baised eQTL |
| rs7782876 | chr7:19715350:C:A | - | 0.0791890449049637 | 0.0293994481745591 | COAD | Female-baised eQTL |
| rs28680279 | chr7:19715359:C:A | - | 0.0791890449049637 | 0.0293994481745591 | COAD | Female-baised eQTL |
| rs11972144 | chr7:19714159:C:G | - | 0.0790825849307028 | 0.0297635769000158 | COAD | Female-baised eQTL |
| rs11972146 | chr7:19714166:C:G | - | 0.0790825849307028 | 0.0297635769000158 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs142076913 | chr7:23951766:C:T | - | 0.175056613918726 | 0.0126002010381607 | READ | Male-baised eQTL |
| rs859526 | chr7:38948311:T:C | - | -0.0860509567262943 | 0.0134782286175799 | KIRC | Male-baised eQTL |
| rs34147895 | chr7:32492184:G:C | - | 0.0562733111773775 | 0.0221635203739955 | KIRC | Male-baised eQTL |
| rs7804609 | chr7:32518482:A:C | - | 0.0533355003972093 | 0.0276741321439903 | KIRC | Male-baised eQTL |
| rs13237495 | chr7:32521075:A:G | - | 0.0520304838842151 | 0.031332283825489 | KIRC | Male-baised eQTL |
| rs863992 | chr7:38949625:G:A | - | -0.0836541644717603 | 0.0375977585016801 | KIRC | Male-baised eQTL |
| rs859525 | chr7:38950036:G:A | - | -0.0836541644717603 | 0.0375977585016801 | KIRC | Male-baised eQTL |
| rs1557941 | chr7:38789747:C:T | - | 0.090398864332056 | 0.0450355498634196 | KIRC | Male-baised eQTL |
| rs2122632 | chr7:32485074:G:A | - | 0.0515688120112312 | 0.0492226550532476 | KIRC | Male-baised eQTL |
| rs12234305 | chr7:38946696:A:T | - | 0.0821889547410892 | 0.0498507600251117 | KIRC | Male-baised eQTL |
| rs7786369 | chr7:31123790:C:T | - | 0.049209789133369 | 0.0245186463902359 | COAD | Male-baised eQTL |
| rs10951279 | chr7:31123061:A:C | - | 0.0490479326214669 | 0.0250616597760638 | COAD | Male-baised eQTL |
| rs12668369 | chr7:31123356:A:G | - | 0.0490479326214669 | 0.0250616597760638 | COAD | Male-baised eQTL |
| rs17677471 | chr7:35497751:G:A | - | 0.0777824592517093 | 0.0252899760300388 | COAD | Male-baised eQTL |
| rs10266700 | chr7:29859259:C:A | - | 0.0791054062001294 | 0.0331907458798177 | COAD | Male-baised eQTL |
| rs12672673 | chr7:31123186:C:G | - | 0.0472595610616129 | 0.0337769833448304 | COAD | Male-baised eQTL |
| rs4644138 | chr7:22843208:T:C | - | -0.039404465365648 | 0.0340915781550475 | COAD | Male-baised eQTL |
| rs4140788 | chr7:31121158:T:G | - | 0.0457728724618696 | 0.0402814589648354 | COAD | Male-baised eQTL |
| rs7803207 | chr7:31120695:A:G | - | 0.0457535944373859 | 0.0403385651696583 | COAD | Male-baised eQTL |
| rs4140789 | chr7:31120763:G:C | - | 0.045285580877791 | 0.0433414954667431 | COAD | Male-baised eQTL |
| rs11975341 | chr7:29825542:A:G | - | 0.06431154981904 | 0.0466140382149517 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000255690 |
| CpG Site: cg00551143 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.259354153194879 | |
 | Gene ID: ENSG00000255690 |
| CpG Site: cg10099601 | |
| Position to Gene: promoter | |
| Male Effect: - | |
| Female Effect: -0.170627435530991 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg00551143 | chr7:28959244 | promoter | -0.259354153194879 | 1.4841225995648e-33 | -0.6951241936808439 | 3.9051031119451873e-38 | LUAD |
| cg10099601 | chr7:28958961 | promoter | -0.170627435530991 | 1.24381309814845e-18 | -0.5583118242961101 | 2.6749351164792103e-22 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of TRIL |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
